Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

October 19, 2015 updated by: Memorial Sloan Kettering Cancer Center

A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

The purpose of this study is to find out what effects, good and/or bad, STA-9090 has on the patient and their breast cancer.

STA-9090 is an experimental drug that works by breaking down cancer proteins. When the cancer proteins are destroyed, the cancer cells die. STA-9090 is an experimental drug that is not yet approved for the treatment of cancer by the United States (FDA) Food and Drug Administration . STA-9090 has been tested in cancer patients in other trials and a safe dose for this drug has been found. We are now interested to see how active this drug is against breast cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Basking Ridge, New Jersey, United States, 07920
        • Memorial Sloan-Kettering at Basking Ridge
    • New York
      • Commack, New York, United States, 11725
        • Memorial Sloan-Kettering Cancer Center at Commack
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Cancer Center
      • Rockville Centre, New York, United States, 11570
        • Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
      • Sleepy Hollow, New York, United States, 10591
        • Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male and Female patients must be at least 18 years of age
  • Pathologically confirmed diagnosis of breast cancer
  • Metastatic or advanced stage breast cancer
  • Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy)
  • Patients with HER2+ disease must have received prior treatment with Trastuzumab
  • Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy
  • Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) ≥ 3 weeks
  • Measurable disease by RECIST 1.1
  • Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • Life expectancy of at least 3 months
  • Adequate hematologic function as defined by:
  • Absolute neutrophil count ≥1,500 cells/μL
  • Platelets ≥100,000/μL
  • Hemoglobin ≥ 9.0g/dL
  • Adequate hepatic function as defined by:
  • Serum bilirubin ≤ 1.5 X upper limit of normal (ULN);
  • Adequate renal function as defined by a serum creatinine ≤ 1.5 x ULN
  • AST, ALT, and alkaline phosphatase ≤ 3 × ULN except for:
  • Patients with hepatic metastases: ALT and AST ≤ 5 × ULN
  • Patients with hepatic and/or bone metastases: alkaline phosphatase ≤ 5 × ULN
  • Patients with Gilbert's disease: serum bilirubin < 5 mg/dL
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Female subjects of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment
  • Female subjects of childbearing age must have a negative serum pregnancy test at study entry.

Exclusion Criteria:

  • Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease
  • Major surgery within 4 weeks prior to first dose of STA-9090
  • Poor peripheral venous access for study drug administration. Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material.
  • History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., Polyethylene glycol [PEG] 300 and Polysorbate 80)
  • Baseline QTc > 470 msec
  • Ventricular ejection fraction (EF) <50% at baseline
  • Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)
  • Women who are pregnant or lactating
  • Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results in the judgment of the investigator
  • Seizure disorder or requirement for seizure medication
  • Prior treatment with an HSP90 inhibitor
  • persistent adverse events of prior therapies that are > 1 grade 1 in severity
  • history of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery
  • history of or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block
  • New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers or diuretics

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: STA-9090
This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Response Rate
Time Frame: Radiological imaging studies to evaluate tumor status will be repeated during the rest week (Days 22 to 28) of every third cycle
To determine the overall response rate using RECIST v 1.1 criteria, defined as PR +CR.using RECIST v 1.1 criteria, defined as Partial response + complete response
Radiological imaging studies to evaluate tumor status will be repeated during the rest week (Days 22 to 28) of every third cycle

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Actual)

September 1, 2013

Study Completion (Actual)

September 1, 2013

Study Registration Dates

First Submitted

January 6, 2011

First Submitted That Met QC Criteria

January 7, 2011

First Posted (Estimate)

January 11, 2011

Study Record Updates

Last Update Posted (Estimate)

November 20, 2015

Last Update Submitted That Met QC Criteria

October 19, 2015

Last Verified

October 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • 10-145

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on STA-9090

Subscribe